Department of Molecular and Integrative Physiology, University of Illinois at Urbana-Champaign, Urbana, Illinois 61801, USA.
J Biol Chem. 2011 Sep 9;286(36):31852-63. doi: 10.1074/jbc.M111.244335. Epub 2011 Jul 11.
Emerging evidence indicates that amyloid β peptide (Aβ) initially induces subtle alterations in synaptic function in Alzheimer disease. We have recently shown that Aβ binds to β(2) adrenergic receptor (β(2)AR) and activates protein kinase A (PKA) signaling for glutamatergic regulation of synaptic activities. Here we show that in the cerebrums of mice expressing human familial mutant presenilin 1 and amyloid precursor protein genes, the levels of β(2)AR are drastically reduced. Moreover, Aβ induces internalization of transfected human β(2)AR in fibroblasts and endogenous β(2)AR in primary prefrontal cortical neurons. In fibroblasts, Aβ treatment also induces transportation of β(2)AR into lysosome, and prolonged Aβ treatment causes β(2)AR degradation. The Aβ-induced β(2)AR internalization requires the N terminus of the receptor containing the peptide binding sites and phosphorylation of β(2)AR by G protein-coupled receptor kinase, not by PKA. However, the G protein-coupled receptor kinase phosphorylation of β(2)AR and the receptor internalization are much slower than that induced by βAR agonist isoproterenol. The Aβ-induced β(2)AR internalization is also dependent on adaptor protein arrestin 3 and GTPase dynamin, but not arrestin 2. Functionally, pretreatment of primary prefrontal cortical neurons with Aβ induces desensitization of β(2)AR, which leads to attenuated response to subsequent stimulation with isoproterenol, including decreased cAMP levels, PKA activities, PKA phosphorylation of serine 845 on α-amino-2,3-dihydro-5-methyl-3-oxo-4-isoxazolepropanoic acid (AMPA) receptor subunit 1 (GluR1), and AMPA receptor-mediated miniature excitatory postsynaptic currents. This study indicates that Aβ induces β(2)AR internalization and degradation leading to impairment of adrenergic and glutamatergic activities.
新出现的证据表明,淀粉样β肽(Aβ)最初会导致阿尔茨海默病患者突触功能出现细微改变。我们最近发现,Aβ与β2 肾上腺素能受体(β2AR)结合并激活蛋白激酶 A(PKA)信号转导,从而调节谷氨酸能突触活动。在这里,我们发现在表达人类家族性突变早老素 1 和淀粉样前体蛋白基因的小鼠大脑中,β2AR 的水平急剧降低。此外,Aβ可诱导转染的人β2AR 在成纤维细胞和原代前额皮质神经元中的内吞作用。在成纤维细胞中,Aβ处理还会诱导β2AR 转运到溶酶体中,并导致β2AR 降解。Aβ诱导的β2AR 内化需要受体的 N 端,该 N 端包含肽结合位点和由 G 蛋白偶联受体激酶磷酸化的β2AR,而不是 PKA。然而,β2AR 的 G 蛋白偶联受体激酶磷酸化和受体内化比βAR 激动剂异丙肾上腺素诱导的过程要慢得多。Aβ诱导的β2AR 内化还依赖于衔接蛋白 arrestin 3 和 GTP 酶 dynamin,但不依赖于 arrestin 2。在功能上,用 Aβ预处理原代前额皮质神经元可诱导β2AR 脱敏,导致对随后异丙肾上腺素刺激的反应减弱,包括 cAMP 水平降低、PKA 活性降低、PKA 对α-氨基-2,3-二氢-5-甲基-3-氧代-4-异噁唑丙酸(AMPA)受体亚基 1(GluR1)丝氨酸 845 的磷酸化和 AMPA 受体介导的微小兴奋性突触后电流减少。本研究表明,Aβ诱导β2AR 内化和降解,导致肾上腺素能和谷氨酸能活性受损。